1. Home
  2. |Insights
  3. |Misleading Discussions Can Be With Awardee

Misleading Discussions Can Be With Awardee

Client Alert | 1 min read | 10.19.06

In Advanced Systems Development, Inc. (Sept. 19, 2006, http://www.gao.gov/decisions/bidpro/298411.pdf), the GAO held that the agency improperly tipped the tables when it incorrectly advised the future awardee in discussions that one portion of its price violated the solicitation's price target and never disclosed that the excess was caused at least in part by an upward adjustment the agency had made to compensate for an error in another part of the awardee's pricing proposal. In response to this incorrect and incomplete information provided during discussions, the offeror lowered its final price below that of the competition, including the protestor, who prevailed on the theory that the agency's discussions with the awardee were not meaningful.

Contacts

Insights

Client Alert | 3 min read | 11.17.26

CMS Final OPPS Rule Will Reduce Reimbursement for 340B Drugs

On November 6, 2026, the Centers for Medicare and Medicaid Services (CMS) published its final 2027 Medicare Hospital Outpatient Perspective Payment System (OPPS) rule. The rule will reduce reimbursement for 340B drugs from average sales price (ASP) plus 6% (what Medicare generally pays for Part B outpatient drugs administered by providers) to ASP minus 28%, a 32% reduction. CMS originally proposed reducing reimbursement to ASP minus 33.4%. CMS indicated that this change will better align Medicare reimbursement with hospitals’ costs of acquiring 340B drugs.  ...